Compagnie Lombard Odier SCmA’s Atara Biotherapeutics ATRA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-180	Closed	-$186K	–	553
2018 Q3	$186K	Hold	180	–	–	0.01%	299
2018 Q2	$165K	Hold	180	–	–	0.01%	304
2018 Q1	$175K	Hold	180	–	–	0.01%	318
2017 Q4	$81K	Hold	180	–	–	﹤0.01%	424
2017 Q3	$74K	Hold	180	–	–	﹤0.01%	486
2017 Q2	$63K	Hold	180	–	–	﹤0.01%	491
2017 Q1	$92K	Buy	180 +80	+80%	+$33.1K	﹤0.01%	459
2016 Q4	$35K	Hold	100	–	–	﹤0.01%	647
2016 Q3	$53K	Hold	100	–	–	﹤0.01%	673
2016 Q2	$56K	Buy	100 +60	+150%	+$28.8K	﹤0.01%	649
2016 Q1	$19K	Hold	40	–	–	﹤0.01%	834
2015 Q4	$26K	Buy	+40	New	+$30.3K	﹤0.01%	770

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ATRA Position: Q4 2018 in Review

Compagnie Lombard Odier SCmA sold out of Atara Biotherapeutics (ATRA) in Q4 2018, closing a stake of 180 shares — an estimated $186K sold.

Compagnie Lombard Odier SCmA first reported a position in ATRA in Q4 2015 and held it in 12 quarters. The position peaked at $186K in Q3 2018. 121 funds tracked by Wall St. Rank hold ATRA as of Q4 2018.

Compagnie Lombard Odier SCmA reported no remaining Atara Biotherapeutics position as of Q4 2018 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 180 Atara Biotherapeutics shares in Q4 2018, an estimated $186K.
Compagnie Lombard Odier SCmA first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 12 quarters.
Compagnie Lombard Odier SCmA's Atara Biotherapeutics position peaked at $186K in Q3 2018.
121 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2018, filed 13 Feb 2019.